Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESPIRE HFpEF: CagriSema versus placebo in heart failure with preserved or mildly reduced ejection fraction and obesity
MOH_2025-03-17_013951Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Feb 2025
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of CagriSema, cagrilintide and semaglutide in heart failure (HF) and obesity (2 arms), sponsored by Novo Nordisk. Primary endpoint: Cardiovascular death and heart failure events. Started Feb 2025; status: completed.
02
Drugs
03
Conditions
heart failure (HF)obesity
Beyond the preview
Go deeper on MOH_2025-03-17_013951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-03-17_013951.